Literature DB >> 3044581

Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers.

M C Hollstein1, A M Smits, C Galiana, H Yamasaki, J L Bos, A Mandard, C Partensky, R Montesano.   

Abstract

Primary esophageal squamous cell carcinomas from 41 patients were analyzed for the presence of proto-oncogene alterations associated with this malignancy. The occurrence of activating ras gene mutations in 25 tumors was determined using oligomer hybridization of target sequences amplified by polymerase chain reaction. We found no evidence for mutations in codons 12 and 61 of the H-ras, K-ras, and N-ras genes, nor in codon 13 of the K-ras and N-ras loci in any of these tumors. The apparent absence of activated ras oncogene in esophageal cancers represents a possible exception to the presence of these mutations found consistently in numerous other types of human malignancies, and is in striking contrast to the 40% prevalence of ras mutations in human colorectal cancers. Southern blot hybridization experiments with DNAs from tumors demonstrated amplification of the epidermal growth factor receptor gene (c-erbB) in two of 25 carcinomas. No amplification of the structurally related c-erbB2 (neu) gene was detected. In three out of 12 carcinomas, the level of epidermal growth factor receptor RNA was significantly higher than in normal esophageal mucosal tissue. Our results suggest that enhanced transcription of the epidermal growth factor receptor gene is associated with the development of some esophageal cancers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044581

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Frequent mutation of the p53 gene in human esophageal cancer.

Authors:  M C Hollstein; R A Metcalf; J A Welsh; R Montesano; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting.

Authors:  Michael J Grieco; H M C Shantha Kumara; Raymond Baxter; Nadav Dujovny; Matthew F Kalady; Vesna Cekic; Martin Luchtefeld; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-03-31       Impact factor: 4.584

3.  Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction.

Authors:  S J Meltzer; J Yin; Y Huang; T K McDaniel; C Newkirk; O Iseri; B Vogelstein; J H Resau
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

Review 5.  Chemoprevention of esophageal squamous cell carcinoma.

Authors:  Gary D Stoner; Li-Shu Wang; Tong Chen
Journal:  Toxicol Appl Pharmacol       Date:  2007-03-15       Impact factor: 4.219

6.  Isolation of differentially expressed genes in carcinoma of the esophagus.

Authors:  M W Graber; C W Schweinfest; C E Reed; T S Papas; P L Baron
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

7.  Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues.

Authors:  Q Y Duh; A E Siperstein; R A Miller; J J Sancho; M J Demeure; O H Clark
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

8.  Esophageal squamous cell carcinoma: pathology and prognosis.

Authors:  H Ide; T Nakamura; K Hayashi; T Endo; A Kobayashi; R Eguchi; F Hanyu
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

9.  c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.

Authors:  Richard Marcotte; Lixin Zhou; Harold Kim; Calvin D Roskelly; William J Muller
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

10.  A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.

Authors:  Michael Lanuti; Geoffrey Liu; Jonathan M Goodwin; Rihong Zhai; Bryan C Fuchs; Kofi Asomaning; Li Su; Norman S Nishioka; Kenneth K Tanabe; David C Christiani
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.